Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Diclofenac Potassium
Therapeutic Area : Undisclosed
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Diclofenac Potassium is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 19, 2021
Lead Product(s) : Diclofenac Potassium
Therapeutic Area : Undisclosed
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Diclofenac Potassium
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Assertio Therapeutics
Deal Size : Undisclosed
Deal Type : Merger
Assertio Completed Merger with Zyla Life Sciences
Details : The merger creates a growing commercial pharmaceutical company with neurology, inflammation and pain products.
Product Name : Cambia
Product Type : Miscellaneous
Upfront Cash : Undisclosed
May 20, 2020
Lead Product(s) : Diclofenac Potassium
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Assertio Therapeutics
Deal Size : Undisclosed
Deal Type : Merger